A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-01-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subject hasleukemiasubject ischemotherapytherapy
  Phrases that lowered it: evaluate theto evaluateinvestigatorlymphomamg
• Sponsor's past termination rate: 16.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 37 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 25.0% (raises risk) · Drug's FDA history
• Keywords listed: 18 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 20377 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 97313 (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 94.2% (raises risk) · Drug's FDA history
• Sponsor's past trials: 170 (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT04231747 · started 2020 · scored riskier than 84% of active trials completed
• Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia NCT02303821 · started 2015 · scored riskier than 68% of active trials completed
• Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma NCT01593696 · started 2012 · scored riskier than 73% of active trials completed
• Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) NCT02393859 · started 2015 · scored riskier than 60% of active trials completed
• CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies NCT04088864 · started 2020 · scored riskier than 94% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.